Biochemical and clinical correlation of intraplaque neovascularization using contrast-enhanced ultrasound of the carotid artery

Atherosclerosis

Volumn 233, Issue 2, 2014, Pages 579-583

  Kim, Hyun Soo ^a   Woo, Jong Shin ^a   Kim, Bu Yong ^a   Jang, Hyun Hee ^a   Hwang, Seung Joon ^a   Kwon, Sung Jin ^a   Choi, Eun Young ^a   Kim, Jin Bae ^a   Cheng, Xianwu ^b   Jin, Enze ^c   Kim, Woo Shik ^a   Kim, Kwon Sam ^a   Kim, Weon ^a  

^a Kyung Hee University   (South Korea)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Biomarker; Carotid enhanced ultrasound; Intraplaque neovascularization; Matrix metalloproteinase 9

Indexed keywords

BIOLOGICAL MARKER; CATHEPSIN L; GELATINASE A; GELATINASE B; CONTRAST AGENT BR1; CONTRAST MEDIUM; CTSL1 PROTEIN, HUMAN; FLUOROCARBON; PERFLUTREN; PHOSPHOLIPID; SULFUR HEXAFLUORIDE;

ADULT; ARTICLE; ATHEROSCLEROTIC PLAQUE; BIOCHEMISTRY; BLOOD LEVEL; CARDIOVASCULAR RISK; CAROTID ARTERY; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); OUTCOME ASSESSMENT; PRIORITY JOURNAL; SUSCEPTIBILITY WEIGHTED IMAGING; AGE; AGED; ARTERIAL WALL THICKNESS; BLOOD; CAROTID ARTERY DISEASE; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; COMMON CAROTID ARTERY; COMORBIDITY; DIAGNOSTIC USE; DOPPLER ECHOGRAPHY; ECHOGRAPHY; PROSPECTIVE STUDY;

AGE FACTORS; AGED; BIOLOGICAL MARKERS; CAROTID ARTERY DISEASES; CAROTID ARTERY, COMMON; CAROTID INTIMA-MEDIA THICKNESS; CATHEPSIN L; COMORBIDITY; CONTRAST MEDIA; FEMALE; FLUOROCARBONS; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHOLIPIDS; PLAQUE, ATHEROSCLEROTIC; PROSPECTIVE STUDIES; SULFUR HEXAFLUORIDE; ULTRASONOGRAPHY, DOPPLER, COLOR; ULTRASONOGRAPHY, DOPPLER, PULSED;

EID: 84896296995     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.01.042     Document Type: Article

References (28)

1. Hermus L., Lefrandt J.D., Tio R.A., Breek J.C., Zeebregts C.J. Carotid plaque formation and serum biomarkers. Atherosclerosis 2010, 213:21-29.
2. Cheng X.W., Huang Z., Kuzuya M., Okumura K., Murohara T. Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications. Hypertension 2011, 58:978-986.
3. Kim K.H., Kim W.H., Park H.W., et al. Impact of plaque composition on long-term clinical outcomes in patients with coronary artery occlusive disease. Korean Circ J 2013, 43:377-383.
4. Kolodgie F.D., Gold H.K., Burke A.P., et al. Intraplaque hemorrhage and progression of coronary atheroma. NEngl J Med 2003, 349:2316-2325.
5. Amato M., Montorsi P., Ravani A., et al. Carotid intima-media thickness by B-mode ultrasound as surrogate of coronary atherosclerosis: correlation with quantitative coronary angiography and coronary intravascular ultrasound findings. Eur Heart J 2007, 28:2094-2101.
6. de Groot E., Hovingh G.K., Wiegman A., et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation 2004, 109:III33-III38.
7. Feinstein S.B., Coll B., Staub D., et al. Contrast enhanced ultrasound imaging. JNucl Cardiol 2010, 17:106-115.
8. Vicenzini E., Giannoni M.F., Benedetti-Valentini F., Lenzi G.L. Imaging of carotid plaque angiogenesis. Cerebrovasc Dis 2009, 27(Suppl.2):48-54.
9. Coli S., Magnoni M., Sangiorgi G., et al. Contrast-enhanced ultrasound imaging of intraplaque neovascularization in carotid arteries: correlation with histology and plaque echogenicity. JAm Coll Cardiol 2008, 52:223-230.
10. Giannoni M.F., Vicenzini E., Citone M., et al. Contrast carotid ultrasound for the detection of unstable plaques with neoangiogenesis: a pilot study. Eur J Vasc Endovasc Surg 2009, 37:722-727.
11. Hoogi A., Adam D., Hoffman A., Kerner H., Reisner S., Gaitini D. Carotid plaque vulnerability: quantification of neovascularization on contrast-enhanced ultrasound with histopathologic correlation. AJR Am J Roentgenol 2011, 196:431-436.
12. Staub D., Patel M.B., Tibrewala A., et al. Vasa vasorum and plaque neovascularization on contrast-enhanced carotid ultrasound imaging correlates with cardiovascular disease and past cardiovascular events. Stroke 2010, 41:41-47.
13. Ding S., Zhang M., Zhao Y., et al. The role of carotid plaque vulnerability and inflammation in the pathogenesis of acute ischemic stroke. Am J Med Sci 2008, 336:27-31.
14. Sluimer J.C., Gasc J.M., van Wanroij J.L., et al. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. JAm Coll Cardiol 2008, 51:1258-1265.
15. Magnoni M., Coli S., Marrocco-Trischitta M.M., et al. Contrast-enhanced ultrasound imaging of periadventitial vasa vasorum in human carotid arteries. Eur J Echocardiogr 2009, 10:260-264.
16. Bigg H.F., Rowan A.D., Barker M.D., Cawston T.E. Activity of matrix metalloproteinase-9 against native collagen types I and III. FEBS J 2007, 274:1246-1255.
17. Blankenberg S., Rupprecht H.J., Poirier O., et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003, 107:1579-1585.
18. Kalela A., Koivu T.A., Sisto T., et al. Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease. Scand J Clin Lab Invest 2002, 62:337-342.
19. Ye Z.X., Leu H.B., Wu T.C., Lin S.J., Chen J.W. Baseline serum matrix metalloproteinase-9 level predicts long-term prognosis after coronary revascularizations in stable coronary artery disease. Clin Biochem 2008, 41:292-298.
20. Lee K., Ahn T.H., Kang W.C., et al. The effects of statin and niacin on plaque stability, plaque regression, inflammation and oxidative stress in patients with mild to moderate coronary artery stenosis. Korean Circ J 2011, 41:641-648.
21. Inokubo Y., Hanada H., Ishizaka H., Fukushi T., Kamada T., Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001, 141:211-217.
22. Wang K.F., Huang P.H., Chiang C.H., et al. Usefulness of plasma matrix metalloproteinase-9 level in predicting future coronary revascularization in patients after acute myocardial infarction. Coron Artery Dis 2013, 24:23-28.
23. Eldrup N., Gronholdt M.L., Sillesen H., Nordestgaard B.G. Elevated matrix metalloproteinase-9 associated with stroke or cardiovascular death in patients with carotid stenosis. Circulation 2006, 114:1847-1854.
24. Dominguez-Rodriguez A., Abreu-Gonzalez P., Garcia-Gonzalez M.J., Kaski J.C. High serum matrix metalloproteinase-9 level predict increased risk of in-hospital cardiac events in patients with type 2 diabetes and ST segment elevation myocardial infarction. Atherosclerosis 2008, 196:365-371.
25. Rundek T., Arif H., Boden-Albala B., Elkind M.S., Paik M.C., Sacco R.L. Carotid plaque, a subclinical precursor of vascular events: the Northern Manhattan Study. Neurology 2008, 70:1200-1207.
26. Muntner P., Mann D., Winston J., Bansilal S., Farkouh M.E. Serum cystatin C and increased coronary heart disease prevalence in US adults without chronic kidney disease. Am J Cardiol 2008, 102:54-57.
27. Hoke M., Amighi J., Mlekusch W., et al. Cystatin C and the risk for cardiovascular events in patients with asymptomatic carotid atherosclerosis. Stroke 2010, 41:674-679.
28. Arcidiacono M.V., Rubinat E., Ortega E., Betriu A., Fernández E., Mauricio D. Pseudo-enhancement does not explain the increased carotid adventitial vasa vasorum signal in diabetic patients. Atherosclerosis 2013, 229:459-461.